MeiraGTx Holdings plc Cash and Restricted Cash
MeiraGTx Holdings plc (MGTX) had Cash and Restricted Cash of $145.37 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $145.37M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $73.76M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $68.19M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $17.11M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $145.37M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $73.76M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $68.19M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $17.11M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $34.42M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $68.61M 10-Q · filed 2026-05-14 | |
| 2024-12-31 | $105.67M 10-Q · filed 2026-08-13 | |
| 2024-09-30 | $125.03M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $101.03M 10-Q · filed 2025-08-14 | |
| 2024-03-31 | $120.27M 10-Q · filed 2025-05-13 | |
| 2023-12-31 | $130.65M 10-K · filed 2026-03-30 | |
| 2023-09-30 | $64.40M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $92.77M 10-Q · filed 2024-08-12 | |
| 2023-03-31 | $68.78M 10-Q · filed 2024-05-09 | |
| 2022-12-31 | $115.52M 10-K · filed 2025-03-13 | |
| 2022-09-30 | $114.71M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $72.11M 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $113.78M 10-Q · filed 2023-05-11 | |
| 2021-12-31 | $137.70M 10-K · filed 2024-03-15 | |
| 2021-09-30 | $143.63M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $172.56M 10-Q · filed 2022-08-11 | $172.56M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $199.41M 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $209.52M 10-K · filed 2023-03-14 | $209.52M 10-K · filed 2021-03-11 |
| 2020-09-30 | $179.34M 10-Q · filed 2021-11-10 | $179.33M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $194.81M 10-Q · filed 2021-08-11 | $194.81M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $210.79M 10-Q · filed 2021-05-11 | $210.79M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $227.36M 10-K · filed 2022-03-10 | $227.36M 10-K · filed 2020-03-11 |
| 2019-09-30 | $253.45M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $204.40M 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $227.40M 10-Q · filed 2020-05-07 | |
| 2018-12-31 | $68.20M 10-K · filed 2021-03-11 | |
| 2018-09-30 | $88.68M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $102.18M 10-Q · filed 2019-08-07 | |
| 2018-03-31 | $32.48M 10-Q · filed 2019-05-14 | |
| 2017-12-31 | $8.67M 10-K · filed 2020-03-11 | |
| 2017-09-30 | $5.42M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $5.33M 10-Q · filed 2018-08-08 | |
| 2016-12-31 | $17.92M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |